Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

Retatrutide significantly reduces the apnea-hypopnea index by up to 34.3 events per hour in adults with moderate-to-severe obstructive sleep apnea and obesity.

• Why it matters: Obstructive sleep apnea is linked to serious health risks, and effective treatments for patients with obesity or overweight are limited, highlighting a critical need for new therapies.
• What they did: Two phase 3, double-blind, randomized, placebo-controlled trials involving 691 adults with moderate-to-severe OSA and BMI ≥27 assessed once-weekly retatrutide (4, 9, or 12 mg) over 80 weeks, measuring changes in AHI and body weight.
• The result: Retatrutide led to greater AHI reductions than placebo, with decreases up to 34.3 events per hour, and caused mean body weight reductions of 12.1% to 22.2%, supporting its potential as an effective treatment option.